strong develop oncolog product
recommend buy rate upgrad tp
previous deriv tp base
estim ep forward look price-to-earnings
give upsid potenti
also increas revenu growth expect
estim base follow factor strong growth
keytruda gardasil bridion anim health
achiev import regulatori mileston keytruda
lynparza lenvima strong growth pipelin
merck deliv strong quarter result due strong growth
keytruda gardasil bridion anim health revenu
increas
keytruda revenu increas
sale growth keytruda due volum growth
market merck continu launch keytruda multipl
new indic global keytruda approv china
treatment adult patient unresect metastat
merck gain approv gardasil china
contribut long-term confid brand
gardasil revenu increas
growth due higher sale asia pacif region
volum growth certain european market
total revenu bridion increas
bridion sale growth period reflect volum
growth market particularli unit state
compani namemerck compani inc new tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric sept week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth merck compani inc septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
anim sale increas
anim segment profit
increas compar prior year growth
driven higher sale companion anim product
primarili bravecto line product livestock
product includ poultri rumin swine product
merck expect revenu
includ slightli posit impact foreign
currenc merck slightli lower non tax rate
assumpt expect
merck expect non ep
current price-to-earnings
price-to-earnings seen huge fluctuat past due
volatil stock price fall ep averag
price-to-earnings expect forward price-to-earnings
merck continu execut well strategi drive top
bottom line perform alloc resourc
effect support commerci opportun near
term make necessari invest
recommend buy rate stock base
perform develop strong
oncolog pipelin expect revenu grow
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date oct ex-dividend date sep last split factor new per last split date feb inform merck compani inc septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg restructur interest incom special oper interest incom incom incom minor net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli merck compani inc septemb
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item merck compani inc septemb
provid oper activ compar
provid oper activ includ up-front payment made merck relat
format collabor eisai also includ payment made merck relat
previous disclos settlement world-wide keytruda patent litig
provid invest activ compar declin
due lower proce sale secur invest well
mileston payment relat collabor bayer higher capit expenditur
use financ activ compar higher use
cash financ activ due higher payment debt payment conting consider
relat prior year busi acquisit lower proce exercis stock option
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end merck compani inc septemb
merck strong commerci execut global keytruda gardasil
bridion product led compani deliv growth
total sale increas compar
includ posit impact foreign exchang sale
growth due higher sale oncolog franchis reflect strong
growth keytruda compani program death
therapi well allianc revenu relat lynparza lenvima
growth also due higher sale hospit acut care franchis
larg attribut bridion inject noxafil well higher sale
addit higher sale anim health product also contribut
total sale declin compar
total intern sale increas
compar
cog increas compar
non-gaap cog cost includ
expens amort intang asset record
connect busi acquisit
gross margin compar
non-gaap gross margin compar
declin gross margin due amort amount
capit potenti futur mileston payment relat collabor
amort unfavor manufactur varianc result part
june cyber-attack well unfavor effect foreign exchang
decreas gross margin off-set lower net impact acquisition-
divestiture-rel cost restructur cost reduc gross
margin ppt compar ppt
total sale increas
compar
posit impact
gross margin
compar
sg expens increas slightli compar
reflect unfavor effect foreign exchang higher
administr cost off-set lower promot direct sell cost
 expens increas compar
increas due charg viralyt limit
viralyt acquisit increas clinic develop spend particular
oncolog collabor well invest earli drug develop
non-gaap expens increas compar
previou year quarter increas reflect higher clinic develop
spend particular oncolog collabor well invest
restructur cost increas compar
incom expens net declin
incom compar incom
effect incom tax rate compar
reflect impact acquisit divestiture-rel cost
restructur cost partial off-set benefici impact foreign earn
compar
gaap ep decreas
compar
non-
gaap ep
compar
net incom decreas compar
non-gaap net incom increas
compar
gaap ep decreas compar
non-gaap ep compar
total revenu increas compar
sale growth period due higher sale
oncolog franchis reflect strong growth keytruda allianc revenu
relat lynparza lenvima higher sale hospit acut care
franchis larg attribut bridion inject noxafil higher sale
vaccin human papillomaviru hpv vaccin gardasil/gardasil
higher sale anim health product
cog increas compar
cost includ expens amort intang asset
record connect busi acquisit
sg expens increas compar
increas due unfavor effect foreign exchang
higher administr cost off-set lower promot sell
 expens increas compar
restructur cost increas
compar incom expens net
incom compar incom
effect tax rate compar
net incom declin compar
ep declin compar
compar
ep declin
compar
merck oper two busi segment pharmaceut anim
segment includ human health pharmaceut
vaccin product health pharmaceut product consist
therapeut prevent agent gener sold prescript
treatment human disord vaccin product consist prevent
pediatr adolesc adult vaccin primarili administ physician
pharmaceut segment revenu increas
compar total revenu increas
compar increas due
growth oncolog vaccin hospit acut care partial off-set lower
sale virolog on-going impact loss market exclus
total revenu pharmaceut segment decreas
compar total revenu declin
compar
total intern revenu increas
compar total intern revenu increas
compar
growth oncolog due signific increas sale
keytruda reflect compani continu launch new
indic global strong momentum treatment patient
nsclc keytruda approv first-lin
oncolog sale reflect allianc revenu relat lynparza
relat lenvima repres merck share profit
product sale net cost sale commerci cost
increas
compar
allianc revenu
relat
lynparza
relat lenvima
keytruda revenu increas compar
total revenu increas
compar
keytruda revenu increas
compar total revenu increas
compar
total intern revenu keytruda increas
compar total revenu increas
compar
sale growth keytruda due volum growth
market merck continu launch keytruda multipl new
indic global sale unit state continu build across
multipl approv indic
sale growth intern market keytruda reflect strong
uptak treatment nsclc merck secur reimburs
major market along growth melanoma hnscc
growth vaccin busi due higher sale gardasil
gardasil vaccin prevent certain cancer diseas caus
hpv growth asia pacif due on-going commerci
launch china growth europ partial off-set lower sale
unit state due continu transit two-dos regimen
increas
compar
sale growth
keytruda due
volum growth
market merck
continu launch
keytruda multipl
gardasil revenu increas compar
total revenu increas
compar
gardasil revenu decreas
compar total revenu declin
compar
gardasil intern revenu increas
compar total revenu increas
compar
gardasil sale growth due higher sale asia pacif region
particularli china reflect continu uptak sinc launch well
volum growth certain european market
proquad/m-m-r ii /varivax revenu increas
compar total revenu increas
compar sale growth
period due higher volum price unit state
volum growth certain european market
proquad/m-m-r ii /varivax revenu increas
compar total revenu increas
compar
proquad/m-m-r ii /varivax intern revenu increas
compar total revenu increas
compar
rotateq revenu increas compar
includ favor effect foreign
exchang total revenu increas compar
increas
compar
increas
compar
rotateq intern revenu increas
compar total revenu increas
compar
rotateq revenu increas
compar total revenu
rotateq sale increas due higher sale unit state
reflect time public sector purchas
zostavax revenu declin compar
total revenu declin
compar foreign exchang favor affect
global sale perform
zostavax revenu declin compar
total revenu declin
compar
zostavax intern revenu declin
compar total revenu declin
compar
zostavax sale declin due lower demand unit state
reflect approv competitor vaccin receiv preferenti
recommend cdc acip octob prevent
shingl zostavax
growth hospit acut care reflect strong global demand bridion
total revenu bridion increas
compar total revenu bridion increas
compar
rotateq revenu
 increas
compar
total revenu
bridion increas
compar
bridion revenu increas
compar total revenu increas
compar
bridion intern revenu increas
compar total intern revenu increas
compar
bridion sale growth period reflect volum growth
market particularli unit state europ
noxafil revenu increas compar
total revenu increas
compar
noxafil revenu increas
compar total revenu increas
compar
noxafil intern revenu increas
compar total revenu increas
compar
noxafil sale growth period reflect higher demand price
unit state well volum growth certain european
market china
invanz revenu decreas slightli compar
total revenu increas
compar
patent provid market exclus invanz expir
novemb compani anticip signific declin
invanz sale futur period result gener competit
bridion sale growth
period reflect
volum growth
market particularli
unit state
noxafil sale growth
period reflect
higher demand
price unit
state well volum
growth certain
european market
invanz revenu decreas compar
total revenu increas
compar
invanz intern revenu increas
compar total revenu increas
compar
cancida revenu decreas compar
total revenu decreas
compar
cancida revenu declin
compar total revenu declin
compar
cancida intern revenu declin
compar total revenu declin
compar
cancida sale declin due gener competit certain
european market eu compound patent cancida expir
total revenu simponi increas
compar total revenu increas
compar increas
revenu due volum growth europ
total revenu remicad decreas
compar total revenu decreas
compar merck lost market
exclus remicad major european market longer
market exclus market territori
decreas
compar
due gener
competit certain
eu compound patent
cancida expir
total revenu isentress isentress hd increas
compar sale growth
reflect higher demand latin america time sale russia
brazil total revenu flat
isentress/isentress hd revenu declin
compar total revenu declin
compar
total intern revenu isentress/isentress hd increas
compar total revenu
increas compar
total revenu zepati declin
compar total revenu declin
compar
zepati revenu declin
compar total revenu zepati declin
compar
total intern revenu zepati declin
compar total revenu declin
compar
zepati sale declin reflect unfavor effect increas
competit declin patient volum particularli unit
state merck anticip sale zepati futur continu
materi advers affect competit lower patient volum
total revenu
hd increas
compar
total revenu
zepati declin
compar
combin global sale zetia vytorin atozet rosuzet declin
compar previou year period total
sale declin compar prior year
global sale declin due declin sale reflect lower
volum price zetia vytorin result gener competit
zetia vytorin lost market exclus unit state decemb
april respect
merck experienc rapid substanti declin zetia
vytorin sale expect declin continu merck lost market
exclus major european market zetia ezetrol april
also lost market exclus certain european market vytorin
adempa revenu increas compar
sale growth due higher sale
adempa revenu declin compar
sale declin due lower profit share
bayer market territori due part lower price unit
state partial off-set higher sale merck market territori
total combin sale januvia janumet increas
compar previou year quarter total revenu
increas compar prior year period
sale growth period reflect volum growth global partial off-set
continu price pressur
sale zetia vytorin
atozet rosuzet
declin
compar previou
increas
compar
total sale nuvar increas compar
total revenu increas
compar
nuvar revenu increas
compar total revenu increas
compar
total intern revenu nuvar increas
compar total revenu increas
compar
sale growth period due higher price unit
state patent provid market exclus nuvar
expir april merck anticip signific declin
nuvar sale futur period result gener competit
total sale nuvar
increas
compar
increas
compar
anim segment includ pharmaceut vaccin product
prevent treatment control diseas major farm
anim sale increas compar
total revenu increas
compar
growth driven higher sale companion anim product
primarili bravecto fluralan line product livestock
product includ poultri rumin swine product
anim revenu increas
compar total revenu increas
compar
total intern revenu anim health segment increas
compar total intern
revenu increas compar
total revenu livestock increas
compar total revenu increas
compar
total revenu increas compar
total revenu increas
compar
total intern revenu increas
compar total revenu increas
compar
total revenu companion anim increas
compar total revenu increas
compar
total revenu increas compar
total revenu increas
compar
total intern revenu increas
compar total revenu increas
compar
total revenu
livestock increas
compar
total revenu
increas
compar
oncolog pipelin highlight merck continu expand oncolog program
advanc develop program keytruda lynparza
merck announc fda accept review supplement
biolog licens applic sbla keytruda accept first-
line treatment metastat squamou non-smal cell lung cancer nsclc
regardless express sbla seek acceler
approv new indic base overal respons rate orr
data pivot phase trial fda grant prioriti
review set pdufa date oct addit data show
signific improv overal surviv os also present make
fifth studi advanc nsclc keytruda demonstr
merck announc result pivot phase studi
evalu keytruda monotherapi first-lin treatment local
advanc metastat non-squam squamou nsclc
tumor proport score without egfr genom tumor
aberr studi keytruda monotherapi result significantli
longer os platinum-bas chemotherapi
merck announc interim data cohort phase
studi evalu keytruda monotherapi patient previous
treat advanc small cell lung cancer sclc find show orr
primari endpoint studi patient sclc cohort
addit pre-specifi exploratori analysi orr
patient whose tumor express combin posit score
merck announc pivot phase trial
investig keytruda first-lin treatment recurr metastat
head neck squamou cell carcinoma hnscc met primari endpoint
os monotherapi patient whose tumor express
merck announc
pivot phase
first-lin treatment
recurr metastat
head neck squamou
os monotherapi
merck announc keytruda approv china
nation drug administr treatment adult patient
unresect metastat melanoma follow failur one prior line
therapi first approv therapi
advanc melanoma china
fda accept grant prioriti review new sbla seek
approv keytruda treatment previous treat patient
advanc hepatocellular carcinoma base data phase
trial fda set pdufa date nov
merck announc fda accept standard review new sbla
keytruda adjuv therapi treatment patient
resect high-risk stage melanoma grant pdufa date feb
sbla base signific benefit recurrence-fre
surviv demonstr keytruda pivot phase
trial conduct collabor
european organis research treatment cancer
fda approv keytruda two new indic acceler
approv regul base tumor respons rate durabl
treatment adult pediatr patient refractori primari
mediastin larg b-cell lymphoma relaps two
prior line therapi
treatment patient recurr metastat cervic
cancer diseas progress chemotherapi whose
tumor express determin fda-approv test
merck announc
keytruda
approv china
administr
treatment adult
patient
unresect
follow failur one
prior line therapi
merck astrazeneca
announc japan
pharmaceut
merck astrazeneca announc posit result random
double-blind placebo-control phase trial lynparza
tablet show women brca-mut brcam advanc ovarian
cancer treat first-lin lynparza mainten therapi
statist signific clinic meaning improv
compar placebo
merck astrazeneca announc japan pharmaceut
medic devic agenc approv lynparza tablet use patient
unresect recurr brcam human epiderm growth factor
receptor breast cancer receiv prior
merck astrazeneca announc european medicin agenc
approv lynparza tablet use mainten therapi patient
platinum-sensit relaps high-grad epitheli ovarian fallopian
tube primari periton cancer complet respons partial
respons platinum-bas chemotherapi regardless brca statu
merck eisai
announc result
merck astrazeneca present data phase studi trial
present new
data analys
lenvima combin
keytruda four
show clinic improv median radiolog lynparza
combin abirateron compar abirateron monotherapi
current standard care metastat castration-resist prostat cancer
merck eisai announc result present new data
analys lenvima combin keytruda four differ
carcinoma head neck advanc renal cell carcinoma
pipelin highlight merck also continu advanc vaccin hiv
infecti diseas pipelin
merck announc fda accept review new sbla
gardasil merck nine-val hpv vaccin expand age
indic use women men year old prevent
certain cancer diseas caus nine human papillomaviru
hpv type cover vaccin fda grant prioriti review
set pdufa date oct
china food drug administr approv gardasil use
girl women year old
merck announc week result phase drive-forward
clinic trial evalu efficaci safeti doravirin dor merck
investig non-nucleosid revers transcriptas inhibitor
combin antiretrovir agent treatment
infect adult patient prior antiretrovir treatment histori
week group treat once-daili dor plu ftc/tdf
achiev viral suppress measur proport
patient achiev rna less copies/ml compar
group treat once-daili ritonavir-boost darunavir
drv plu ftc/tdf
china food drug
gardasil use
girl women
tabl show pipelin product develop differ phase
phase reviewcanc keytruda advanc solid tumor cutan squamou cell carcinoma ovarian lenvima biliari tract endometri non-small-cel cavatak melanomabacteri infect relebactam imipenem/cilastatin octob molecular entities/vaccineshiv doravirin eu doravirine/lamivudine/tenofovir disoproxil fumar eu pediatr hexaval combin vaccin keytruda breast octob colorect novemb esophag decemb gastric may eu hepatocellular may nasopharyng april renal octob small-cel lung may lynparza pancreat decemb prostat april endometri june supplement filingscanc keytruda combin carboplatin pemetrex cancer eu first non-squam non-small-cel lung first- metastat squamou non-small-cel lung cancer second head neck squamou cell carcinoma eu second- hepatocellular carcinoma lynparza second metastat breast cancer eu lenvima first- hepatocellular carcinoma eu hiv infect march vaccin march neurofibromatosi type failur vericiguat septemb zoster inactiv vzv vaccin decemb june develop collabor develop current hold registr develop combin investig pediatr hexaval combin vaccin develop approv commerci partnership merck sanofi novemb fda issu respect merck sanofi provid respons deem complet accept review merck compani inc septemb
revenu expect
gaap ep expect non-gaap ep expect
gross margin expect lower year-over-year ppt slight
chang due adempa milestone-rel amort quarter
merck expect oper expens increas year-over-year low mid-
tax rate expect non- tax rate
expect
merck expect share outstand end year
gaap ep expect
non-gaap ep
expect
tax rate
expect
non-gaap tax
rate expect
merck deliv strong perform quarter increas
revenu growth due strong commerci
execut global keytruda gardasil bridion
keytruda revenu increas compar
sale growth keytruda due volum
growth market merck continu launch keytruda multipl new
keytruda approv china treatment adult patient
unresect metastat melanoma follow failur one prior
therapi first therapi approv china advanc
vaccin busi also import growth driver merck recent gain
approv gardasil china contribut long-term
confid brand gardasil revenu increas
gardasil sale growth due higher sale asia pacif
region particularli china reflect continu uptak sinc launch well
volum growth certain european market
total revenu bridion increas bridion
sale growth period reflect volum growth market
particularli unit state europ
anim sale increas anim
segment profit increas compar
prior year growth driven higher sale companion anim product
primarili bravecto line product livestock product includ
poultri rumin swine product
merck solidifi leadership immuno-oncolog along key
pillar growth includ anim health merck confid growth
strength busi
perform
quarter increas
revenu
due strong
global keytruda
merck solidifi
leadership immuno-
oncolog along
key pillar
merck
confid strength
busi
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
gross margin ttm basi compar due increas cog
revenu growth ttm basi compar
oper margin decreas ttm basi compar due increas
ep declin ttm basi compar due decreas net margin
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc septemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale merck compani inc septemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn asset merck compani inc septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item merck compani inc septemb
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free merck compani inc septemb
current price-to-earnings price-to-earnings seen huge fluctuat past
year due volatil stock price fall ep averag price-to-earnings
expect forward price-to-earnings
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form kenneth willi weir mirian robert adam michael juli richard institut holdersholdershar report outvaluevanguard group inc wellington manag compani capit world price row associ northern trust jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf incom fund america washington mutual investor vanguard institut fund-institut vanguard specialized-health vanguard/wellington fund ishar fidel merck compani inc septemb
developmentsfda grant prioriti review merck applic keytruda pembrolizumab monotherapi first-lin treatment local advanc astat non-smal cell lung cancer patient whose tumor express tp announc fda accept review grant prioriti review new supplement biolog licens applic sbla seek approv keytruda merck therapi monotherapi first-lin treatment local advanc metastat nonsquam squamou non-smal cell lung cancer nsclc patient whose tumor express tumor proport score tp withoutegfroralkgenom tumor aberr applic base data pivot phase trial one five phase clinic trial keytruda nsclc demonstr signific improv overal surviv fda set prescript drug user fee act pdufa target action date jan zerbaxa ceftolozan tazobactam primari endpoint non-inferior compar meropenem pivot phase studi adult patient hospital-acquir bacteri pneumonia ventilator-associ bacteri pneumoniaseptemb co inc announc pivot phase clinic studi evalu compani antibiot zerbaxa investig dose treatment adult patient either ventil hospital-acquir bacteri pneumonia habp ventilator-associ bacteri pneumonia vabp met pre-specifi primari endpoint demonstr non-inferior meropenem activ compar day all-caus mortal clinic cure rate test-of-cur visit zerbaxa current indic adult patient treatment complic urinari tract infect includ pyelonephr caus certain gram-neg microorgan indic combin metronidazol adult patient treatment complic intra-abdomin infect caus certain gram-neg gram-posit microorgan eisai merck announc china nation medic product administr nmpa approv lenvima lenvatinib treatment unresect hepatocellular carcinoma septemb co ltd merck announc china nation medic product administr nmpa approv kinas inhibitor lenvima lenvatinib singl agent treatment patient unresect hepatocellular carcinoma receiv prior system therapi china applic lenvima submit octob design prioriti review nmpa due lenvima signific clinic benefit compar exist treatment lead approv approxim month approv mark first lenvima china incid high first new system therapi approv first-lin treatment unresect china ten year fda approv merck delstrigo doravirin lamivudin tenofovir disoproxil fumar once-daili fixed-dos combin tablet complet regimen pifeltro doravirin nnrti treatment appropri patientsaugust announc food drug administr fda approv two new medicin delstrigo once-daili fixed-dos combin tablet doravirin mg lamivudin mg tenofovir disoproxil fumar tdf mg pifeltro doravirin mg new non-nucleosid revers transcriptas inhibitor nnrti administ combin antiretrovir medicin delstrigo pifeltro indic treatment infect adult patient prior antiretrovir treatment experi administ oral daili without food delstrigo contain box warn regard post-treat acut exacerb hepat hbv infect delstrigo pifeltro cure infect aid merck compani inc septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
vs
gross margin ttm
industri
averag
roa roe roi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc septemb
consensu view analyst trend stock
forecast
lower
forward price-to-earnings
lower
valuat comparisonmrkindustri avg avgprice/earn yield avgfive-year growth forecast usdgrowth high day day day estim merck compani inc septemb
consensu view analyst trend stock
averag earn estim current
qtr next qtr
sale growth estim current qtr
next qtr
averag revenu estim current
qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr analyst recommend
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price show upward trend quarter surg
merck gave return quarter averag daili volum share
stock price show upward trend sinc april due regulatori approv drug
stock gave return past one year rang
stock price volatil till april show upward trend sinc april
expect stock price movement momentari rise merck give better-than-
merck deliv strong result quarter growth revenu growth due strong
perform product keytruda gardasil bridion merck got regulatori approv oncolog
product strengthen product pipelin recommend buy rate stock base
perform tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
